Pre-operative image-guided biopsy of breast lesions is a well established step in the diagnostic algorithm of both screen-detected and symptomatic breast lesions. The safety and reliability of stereotactic biopsy is now well established and surgical biopsy is only required in cases where image-guided biopsy is inconclusive. Impalpable breast lesions present a challenge to the surgeon and the role of a radiologist to perform image-guided breast biopsy becomes imperative. Detailed protocols and established guidelines allow for a high pre-operative diagnosis rate. As per the 2015-16 National Health Services Breast Screening Programme (NHSBSP)/Association of Breast Surgery audit of screen-detected cancers, 97 per cent of malignancies were diagnosed preoperatively. The pickup rate was as high as 99 per cent for invasive cases and 92 per cent for in situ cases. An accurate diagnosis not only allows for a detailed discussion on the treatment modalities and prognostication in malignant cases but is also important to avoid unnecessary surgical interventions in case of benign lesions.

Breast lesions identified on mammography or digital breast tomosynthesis (DBT) that appear...
suspicious require tissue diagnosis to plan further management. If the lesions are visible on ultrasound, it is preferable to biopsy them under ultrasound guidance\(^1\). However, occasionally, these lesions or abnormalities are not visible on ultrasound at all, or even if visible, are not clear enough to perform an ultrasound-guided biopsy. This is especially true with microcalcifications demonstrated mammographically\(^3\). Stereotactic biopsy is thus used for suspicious non-palpable lesions identified on mammography or DBT but not visible on ultrasound\(^1\).

History

Before the late 1980s, impalpable breast lesions visualized well only on mammograms were a diagnostic challenge\(^4\). Mammography-guided localization of these had to be performed either with a wire, visible dye or carbon particles, followed by an open surgical biopsy\(^4\). As a mammogram is a two-dimensional image and breast a three-dimensional structure, the third dimension, \textit{i.e.} the depth of the lesion from the skin, had to be assessed by the radiologist. Although experienced breast radiologists devised their own methods of determining this measurement, this was not an exact science\(^4\). This technique is still used commonly for pre-operative wire localizations of impalpable breast lesions, although radiological percutaneous biopsy cannot be done by this method as it lacks the precision that is demanded for a percutaneous biopsy.

The error rate for wire-guided surgical biopsies ranged between two and 22 per cent\(^4\). Specimen radiographs were performed for most but not all lesions\(^5\). Incomplete removal of some lesions due to areas with multiple calcifications, needle migration post-localization and lack of communication between the localizing radiologist and the operating surgeon have been reported as some reasons\(^6\). Furthermore, surgery carried a small risk of mortality due to the general anaesthesia\(^4\). Risks of bleeding, infection, wound healing and breast deformity if large areas were excised were other issues\(^4\).

To start with, stereotactic fine-needle biopsies were performed and cytology was used to confirm the diagnosis of sampled lesions\(^7\). As core biopsy (CB) methods became available, this was soon replaced by CB. In the early 1980s, Dr Per G. Lindgren, a Swedish radiologist in conjunction with Radi Medical Systems in Uppsala, Sweden, developed an automated biopsy device, which was the first version of the automated biopsy guns used today\(^4\). In 1988, an upright fine-needle stereotactic breast biopsy system was adopted which accommodated the automated gun and the Stereotix breast biopsy system (General Electric Medical Systems, Milwaukee, WI, USA) came into being\(^4\). The Fischer prone table was also modified to accommodate the stereotactic biopsy unit which resulted in more comfortable biopsies for the patients. Dr Parker’s first stereotactic CB on August 8, 1988, revolutionized how women with lesions seen only on mammography would be biopsied and treated\(^4\). Thereafter, a number of studies established stereotactic biopsy as the alternative to open surgical biopsy\(^7,9\). Radiologists Fred Burbank, Steve H. Parker, William R. Brody and Elias Zerhouni and a surgeon Thomas J. Fogarty successfully developed Mammatome (Biopsys Medical Instruments, Inc., San Juan Capistrano, CA, USA), the first vacuum-assisted breast biopsy (VABB) device\(^1\). The first VABB was performed on August 5, 1994 and multiple studies have established its success, especially to biopsy microcalcifications demonstrated on mammograms\(^10,11\). With the advent of DBT, DBT-guided stereotactic biopsy was performed especially for lesions that are demonstrated on DBT alone.

Indications

Stereotactic biopsy is indicated in many different clinical scenarios. An impalpable suspicious breast lesion poorly visible or not visualized at all on ultrasound but well demonstrated on mammograms is the most common indication for stereotactic biopsy. Real-time visualization of biopsy needle traversing the lesion, absence of ionizing radiation, better patient comfort, shorter procedure time and lower costs are some of the important advantages of ultrasound-guided biopsy\(^12\). Even some palpable lesions may benefit from stereotactic biopsy, especially those which are vaguely palpable, small, deep seated, not well demonstrated on ultrasound but better demonstrated on mammograms\(^13\).

The lesions that require biopsy are guided by the categorization of lesions according to the Breast Imaging Reporting and Data System, Breast Imaging Atlas (BI-RADS®)\(^14\). BI-RADS 5 (lesions that are assessed as highly suggestive of malignancy) and BI-RADS 4 (lesions that are assessed as suspicious for malignancy) abnormalities should be biopsied in the absence of clinical contraindication for biopsy\(^15\). These include masses, architectural distortions, developing asymmetries and calcifications. To plan the treatment options in presence of synchronous breast
cancer, biopsy confirmation of BI-RADS 3 (probably benign) lesions may be necessary. In addition, histological confirmation of BI-RADS 3 lesions may be required in patients awaiting organ transplantation or women planning to become pregnant\textsuperscript{15}. Absence of MRI-guided biopsy facility in a centre is also a reason for stereotactic biopsy provided it can be reliably established that the lesion on the mammogram is undoubtedly the MRI-detected lesion that needs to be biopsied. Lesions that are only visualized on DBT can also be biopsied stereotactically under tomosynthesis guidance\textsuperscript{16}.

Stereotactic guided wire localization can be performed prior to breast conservation surgery for biopsy-proven impalpable lesions that require excision. The computer calculates the third dimension which needs to be decided by the operator in standard mammography localizations. Pre-operative stereotactic localization may be performed with radioactive seeds also\textsuperscript{17}.

**Equipment**

There are essentially four components of the equipment required for a stereotactic procedure: the stereotactic unit, a device for patient positioning, a computer and the biopsy equipment.

**Stereotactic unit:** Stereotactic biopsy can be carried out using either a dedicated prone table with the patient lying prone or an upright mammographic add-on system with the patient in a sitting or lateral decubitus position. An add-on stereotactic localization device can be fitted on the mammography machine prior to the biopsy which converts a standard mammography machine into a stereotactic biopsy unit\textsuperscript{18}. As the same machine is used for both mammography as well as biopsy purposes, lesion visualization at the time of biopsy is good, as the resolution and quality of the image remains the same\textsuperscript{16}. Alternatively, a purpose-built prone table can be used for stereotactic biopsy\textsuperscript{4}. The prone table is elevated and the breast that hangs inferiorly through an aperture in the prone table is biopsied. The advantages of the prone system are lesser patient movement during the procedure and a reduction in anxiety on part of the patient. This is because the biopsy is performed by the operator sitting on a chair underneath the elevated prone table, and hence, the patient cannot see the biopsy needle or the procedure\textsuperscript{16}. The prone systems also minimize vasovagal reactions compared to the upright add-on systems. However, this system is expensive and requires more space. This is because unlike the upright add-on system, it cannot be used to perform routine mammography, and therefore, separate mammography and biopsy rooms are required. Furthermore, the elderly and those with orthopaedic problems find lying prone during the procedure uncomfortable\textsuperscript{19}.

**Patient carrier:** The patient needs to be comfortable during the procedure as the procedure may take up to 15-30 min. Movement-related complications are directly proportional to patient discomfort. Dedicated stereotactic biopsy chairs are available which allow biopsies in the sitting up and decubitus positions. However, propping up the patient and supporting the back and arms is vital. If a prone table is being used, the patient should be comfortably positioned and good padding provided where required (Fig. 1).

**The computer/monitor:** This is the brain of the procedure which uses the concept of Stereotaxis\textsuperscript{20} and calculates the depth of the lesion. A dedicated computer could be used as is usually the case when a prone table is used for the procedure. Alternatively, the high-end monitor in the mammography room used by the technician to check the adequacy of acquired mammography images could also be used.

Stereotactic biopsy is therefore a method of precise positioning of a needle and sampling of a lesion after calculating the three-dimensional co-ordinates of the lesion. The X- and Y-axis co-ordinates of the centre of the lesion to be biopsied are easily available from the 2D images of mammography. A ‘scout’ image is acquired at an angle of 0°. A +15° image and a −15° image (the stereo pair) are acquired next. It can be noted that the lesion shows an apparent movement between these projections referred to as ‘parallax shift’ and is calculated relative to the reference point (which is unique for different machines). Basic trigonometry is applied to determine the X-, Y- and Z-axis of the lesion to be biopsied\textsuperscript{21}. This is calculated by

![Fig. 1. Illustration of a patient lying on a prone table, with compressed breast, for stereotactic biopsy.](image-url)
the software in the computer using information from the markings done by the operator on the computer screen and mimics depth perception performed by the human brain (Fig. 2).

The biopsy device: Fine-needle aspiration cytology (FNAC) has now been replaced by 14 gauge CB based on evidence from several studies that demonstrated suboptimal accuracy of FNAC for non-palpable breast lesions in general and microcalcifications in particular\textsuperscript{22}. In the Indian population too, the sensitivity and specificity of FNAC are significantly lower than CB and diagnostic categorization with CB is significantly better compared to FNAC\textsuperscript{23}. In fact, the accuracy of stereotactic CB has been reported to be equivalent to that of open surgical biopsies and CB is highly reproducible and reliable\textsuperscript{24-26}. In this context, the importance of radiology pathology concordance cannot be overstated. In cases of discordance between radiological assessment and pathology report, re-biopsy and sometimes open surgical biopsy may be required\textsuperscript{25}. Some studies have shown that CB and 11 gauge VABB are equally accurate at diagnosing microcalcifications with no significant difference in surgical outcome\textsuperscript{27}. Other studies have shown that VABB has some advantages over CB. VAAB increases pre-biopsy confidence for some difficult lesions. The biopsy action of VABB is directional and it can acquire tissues up to 5 mm away from its own position, as the vacuum action can draw the lesion into the sampling chamber and cut it away from the surrounding tissue, compensating for subtle patient movements\textsuperscript{28}. Ductal carcinoma in situ (DCIS) is more frequently underestimated with CB than with VABB\textsuperscript{29}.

First-line VABB use may be considered if the cluster of microcalcification is small (<5 mm) or the calcification is scanty\textsuperscript{30}. If representative microcalcification is not demonstrated on specimen radiography, a repeat biopsy by means of VABB is advisable. Furthermore, repeat biopsies for masses or architectural distortions are preferably done by VABB\textsuperscript{31}. The availability of equipment, local expertise and departmental protocol dictate the choice of CB vs VABB.

The procedure

An unambiguous well demonstrated target is a prerequisite for a good biopsy. A clear protocol detailing all the steps is important for a successful stereotactic biopsy. A written informed consent must be obtained after advising the patient about the compression applied during the procedure, low dose of radiation to the breast and time taken for the procedure along with the risks of bleeding, infection and pain. History of drug allergy must be elicited, with specific reference to lignocaine. The importance of staying still during the procedure should be stressed upon to improve compliance.

View/direction of compression & approach: The mammographic view used for the procedure/direction of compression of the breast should be decided. Cranio-caudal, mediolateral, lateromedial or oblique views of breast can be used for the procedure. The determination of direction of compression is based on best lesion visualization, shortest distance from skin to lesion and avoidance of arteries\textsuperscript{17}. The approach could be vertical or lateral. In the vertical approach, the needle is inserted perpendicular to the compression paddle. For example, if the breast is compressed in the cranio-caudal view and a vertical approach is taken, the needle will also travel cranio-caudally, that is entering the superior aspect of the breast and moving towards the image receptor. However, if the breast is compressed in the cranio-caudal view, and a lateral approach is taken, the needle will travel perpendicular to the cranio-caudal direction, that is entering the breast from the lateral aspect or the medial aspect of the breast, and hence not pointing to the image receptor. In the lateral approach, the needle is parallel to the compression paddle\textsuperscript{32}. The approach taken is irrespective of whether the underlying view/compression is cranio-caudal, mediolateral, lateromedial or oblique (Fig. 3)\textsuperscript{32}. The breast size, breast thickness upon compression as well as the location of the lesion influence the approach\textsuperscript{17}. The view/direction of compression and the approach...
should be decided prior to consenting and should be explained to the patient (Fig. 4).

**Positioning:** The technician positions the patient compressing the breast in the predetermined view for the predetermined approach. The lady’s breast is compressed between the compression plate and the image receptor in the stereotactic unit in such a way that the target is at the centre of the biopsy window of the compression paddle. This is confirmed by taking the 0° scout view which should ideally demonstrate the centre of the lesion to be biopsied at the centre of the image. Then, the +15° and −15° stereo pair images are obtained by moving the X-ray tube and detector assembly +15° and −15° relative to the 0° position on the scout image. Thus, a pair of images with 30° separation between projections are obtained. These are displayed on the monitor in the biopsy room. Apparent movement or parallax shift is clearly demonstrated on the images. The operator marks the centre of the lesion on the +15° and −15° images on the screen of the monitor. The X, Y and Z co-ordinates of the centre of the lesion to be biopsied are calculated by the computer and then transferred to the upright add-on stereotactic biopsy unit or the prone table biopsy unit.

**The biopsy:** The operator cleans the skin and injects local anaesthesia. One per cent or two per cent lignocaine is used for CB. For VABB lignocaine one per cent for skin and lignocaine one per cent combined with 1:100,000 epinephrine can be used. Epinephrine is avoided for skin anaesthesia to avoid skin necrosis. A small skin bleb is raised followed by deeper injection in both CB and VABB. A 2 mm skin incision is made for a CB, the needle is inserted and pre-fire and post-fire check images are taken to confirm optimum needle position. For VABB, a larger 4 mm incision is made and firing may not be required and hence, a single set of check or positioning images may be acquired. VABB needles range from 7 to 11 gauge. Depending on the type of lesion and size of the biopsy needle, on an average, 6-12 samples are obtained. However, no fixed number guarantees optimum sampling and decision about the number of samples and adequacy should be made on an individual basis. It is accepted that more number of cores need to be acquired for microcalcifications compared to masses. In addition, architectural distortions usually need more cores so as
not to miss a small malignancy or radial scar within them\textsuperscript{16}.

\textbf{Post-biopsy:} Checking the adequacy of sampling of microcalcifications with magnification view of samples acquired is compulsory to confirm that appropriate tissue sampling has been performed\textsuperscript{15}. The biopsy specimen is usually radiographed by laying the tissue on a moist paper or Petri dish\textsuperscript{35}. Furthermore, the plastic lid of the formalin pot can be used to radiograph the samples. Following this, the tissue samples are placed in a 10 per cent formalin solution with appropriate patient identification\textsuperscript{35}. Marker clip is placed if the lesion biopsied is small and the operator is concerned that the lesion may have been totally removed. It could also be placed if the operator thinks that it may not be unambiguously visible on the mammograms after biopsy, making presurgical mammography-guided wire localization difficult. In some cases, the marker clip can also be placed if there is a doubt that the mammographically visualized lesion may not correspond to the sonographically visualized lesion. If a marker clip is placed, lateral and craniocaudal mammograms are performed immediately after the procedure to confirm its position\textsuperscript{19}. Important pitfalls and solutions are described in Table. In smaller breasts, the post-fire needle may pass through the breast and strike the image receptor. This is referred to as NSM. An inbuilt safety mechanism does not allow the operator to start the procedure. This can also occur in normal sized breasts if the target is too deep (Fig. 5). The air gap technique to prevent this is described in Figure 6. The technique for skin protection in superficial lesions is shown in Figure 7.

\textbf{Stereotactic biopsy and anti-coagulation}

Stereotactic breast biopsy is considered to be associated with a low risk of bleeding. While for CB, pre-biopsy coagulation profile tests are recommended only in the case of a personal or family history of bleeding problems or if the patient is on anticoagulation therapy\textsuperscript{19}, most centres prefer a clotting screen prior to VABB. However, studies carried out on women on
warfarin have shown no significant increase in the risk of hematoma or bruising compared to patients not on anti-coagulation. In our practice, INR is preferred to be less than 1.5 before undertaking stereotactic biopsies.

Some of the commonly encountered medications associated with increased risk of bleeding are oral vitamin K antagonists (warfarin), oral anti-platelet agents (aspirin, clopidogrel, prasugrel, ticagrelor, cilostazol and dipyridamole) and non-steroidal anti-inflammatory drugs (ibuprofen and diclofenac sodium). Warfarin should ideally be discontinued for five days before the intervention with a target INR <1.5. In cases where stopping warfarin is deemed unsafe for so long, heparin should be used during this period. Warfarin can be re-started within 12 h after the procedure.

Procedural issues

Inability to visualize the target breast lesion at the time of biopsy is an absolute contraindication. Neuromuscular disorders such as Parkinson’s disease may limit the capacity of the patient to lie still. For most prone tables, there is a weight limit generally between 136 and 158 kg.

Pain, infection and hematoma are the known complications of stereotactic breast biopsy. The risk of significant hematoma after CB is one per cent and for VABB is approximately four per cent. Manual pressure over the biopsy site for 5-10 min minimizes hematoma formation. A compression dressing applied for 4-6 h should be considered after VABB, especially after complete lesion excision procedures such as excision of radial scars. Displacement of malignant epithelium is not seen after stereotactic breast biopsies. No cases of significant needle track seeding have been reported from large studies. The operator, technologist and nurse should all be optimally trained and experienced to ensure quality assurance of the procedure. Quality assurance instructions and advice from the manufacturers should be followed to ensure that the equipment is in optimum condition. Quality assurance tests for the mammography machine must be performed as per the Atomic Energy Regulatory Board (AERB), India regulations.

Concordance between the radiological appearance and the pathology result has to be established and close communication and collaboration between the breast radiologist and pathologist is required for this to happen. In case of discordance between the histological and radiological findings or inadequate sampling, a multidisciplinary meeting should be held to plan further management.

Global Scenario

Globally, the most common lesion biopsied stereotactically is microcalcification and stereotactic biopsies are the most accepted for their assessment. Screening programmes in many countries have resulted in an increase in the detection of microcalcifications, which are often a feature of DCIS. In the UK, this has led to an increase in the age-standardized incidence of DCIS from three per 100,000 before the advent of the National Health Service Breast Screening Programme (NHSBSP) to 23 per 100,000 in 2013. The introduction of digital mammography has further increased the detection of microcalcifications. Data from multiple national screening programmes indicate that the recall rate and resulting biopsy for calcifications range from 0.4 to 2 per cent of females screened.
Breast screening coverage is defined as the percentage of women residents eligible for screening at a particular point in time who actually attended their breast screening appointment. The NHSBSP has set and achieves a minimum standard of 70 per cent. However, BreastScreen Australia has set a minimum standard of 70 per cent but achieves about 54.6 per cent. Multiple factors influence breast screening coverage. Awareness of the importance of breast screening as well as ethnicity is known to influence uptake and countries have introduced additional measures to encourage uptake of screening programmes among women from culturally and linguistically diverse backgrounds.

Screening mammography inevitably leads to additional biopsies. However, the risk of false positives and need for additional biopsies have to be weighed against the lives saved by early diagnosis of breast cancer as well as the reassurance provided by biopsy-confirmed benign lesions.

According to published data, the minimum recall rate for calcifications following mammograms is 0.4 per cent of women screened. A diagnosis of malignancy is made after investigations for microcalcifications in 0.3 per cent of women screened. Of the malignancies based on calcifications alone, one-third tend to be invasive cancers. The remaining two-third comprise DCIS. DCIS detected by mammographic screening is predominantly of high nuclear grade and only 13 per cent is low grade. Supplementary contrast-enhanced MRI of the breast and deep learning artificial intelligence methods may help reduce the false-positive rate and hence reduce overdiagnosis and overtreatment of DCIS in the future.

Possible numbers of stereotactic biopsies in India

In India, lack of a national database or screening programme makes it difficult to accurately assess the number of stereotactic breast biopsies needed annually in India. Limited number of sub-specialist radiologists and specialist referral centres coupled with a lack of awareness regarding breast diseases in the community make population-based screening difficult in India at present. In urban India, an increase in awareness and facilities has led to opportunistic mammographic breast screening.

To get an idea about the requirement of stereotactic biopsy, inferences have to be drawn from the census data in concurrence with the guidelines issued by the Breast Imaging Society, India (BISI). The guidelines state that the potential population for screening are women between 40 and 70 yr of age. As per the Indian census of 2011, there were 587,584,719 women in India, constituting 48 per cent of the Indian population. Of these 405,967,794 (69%) reside in rural and 181,616,925 (31%) in urban India. In 2016, 24.8 per cent (n=145,721,010) women were between the age of 40-70 and were the potential population for screening as per the guidelines of BISI.

Even if one considers that only the eligible urban population participated in screening, the number of mammograms annually would be approximately 43,716,303. If 0.4 per cent of these, were recalled for biopsy, which is the minimum recalled for assessment of microcalcifications after screening mammograms, the number of estimated stereotactic biopsies would be 174,865 per annum nationally.

Assuming a procedure time of one hour which includes consenting, planning, actual procedure and aftercare, a dedicated breast unit performing eight stereotactic breast biopsies per day with 25 working days per month would be able to perform 2400 procedures/annum. This would mean approximately 75 breast centres...
with stereotactic biopsy facilities would be needed in the country to meet the demands for urban women alone.

Setting up specialist breast units in rural and remote areas of the country is not a viable model, in fact a hub and spoke model best suits our country whereby mammography can be performed in multiple spoke centres which have a central specialist hub where stereotactic biopsy can be performed. This helps us provide this specialist biopsy technique to a larger geographic area. The spoke hospitals or diagnostic centres can use their resources better and ensure a much wider reach. The hub at the same time can provide specialist service with improved expertise in a financially viable milieu.

Overall, stereotactic breast biopsy is an important component in the armamentarium necessary to provide a comprehensive breast diagnosis and treatment programme. It has a well-established role in biopsying lesions that are visible on mammograms alone, thereby minimizing the number of open surgical biopsies. In the absence of a national breast screening programme and limited resources in India, a hub and spoke model appears to be a viable model for healthcare providers to consider.

Acknowledgment: The author thanks Mr Suprit Brahma for the hand-drawn figures in this manuscript.

Financial support & sponsorship: None.

Conflicts of interest: None.

References

1. O’Flynn EA, Wilson AR, Michell MJ. Image-guided breast biopsy: State-of-the-art. Clin Radiol 2010; 65 : 259-70.
2. Association for Breast Surgery. Best practice guidelines for surgeons in breast cancer screening. Available from: https://associationofbreastsurgery.org.uk/media/64276/final-screening-guidelines-2018.pdf, accessed on July 31, 2021
3. Soo MS, Baker JA, Rosen EL. Sonographic detection and sonographically guided biopsy of breast microcalcifications. AJR Am J Roentgenol 2003; 180 : 941-8.
4. Burbank F. Stereotactic breast biopsy: Its history, its present, and its future. Am Surg 1996; 62 : 128-50.
5. Landercasper J, Gundersen SB Jr, Gundersen AL, Cogbill TH, Travelli R, Strutt P. Needle localization and biopsy of nonpalpable lesions of the breast. Surg Gynecol Obstet 1987; 164 : 399-403.
6. Yankaskas BC, Knelson MH, Abernethy ML, Cuttino JT Jr, Clark RL. Needle localization biopsy of occult lesions of the breast. Experience in 199 cases. Invest Radiol 1988; 23 : 729-33.
7. Lovin J, Parker S, Jobe W, Leuthke J, Hopper K. Stereotactic percutaneous breast core biopsy technical adaptation and initial experience. Breast Dis 1990; 3 : 135-43.
8. Parker SH, Lovin JD, Jobe WE, Luethke JM, Hopper KD, Yakes WF, et al. Stereotactic breast biopsy with a biopsy gun. Radiology 1990; 176 : 741-7.
9. Parker SH, Lovin JD, Jobe WE, Burke BJ, Hopper KD, Yakes WF. Nonpalpable breast lesions: Stereotactic automated large-core biopsies. Radiology 1991; 180 : 403-7.
10. Parker SH, Stavros AT, Dennis MA. Needle biopsy techniques. Radiol Clin North Am 1995; 33 : 1171-86.
11. Parker SH, Dennis MA, Stavros AT. Critical pathways in percutaneous breast intervention. Radiographics 1995; 15 : 946-50.
12. American College of Radiology. ACR practice parameter for the performance of ultrasound-guided percutaneous breast interventional procedures. Available from: https://www.acr.org/-/media/acr/files/practice-parameters/us-guidedbreast.pdf, accessed on July 31, 2021.
13. Expert Panel on Breast Imaging, Moy L, Heller SL, Bailey L, D’Orsi C, DiFlorio RM, et al. ACR appropriateness Criteria § palpable breast masses. J Am Coll Radiol 2017; 14 : S203-24.
14. American College of Radiology. ACR BI-RADS® atlas, breast imaging reporting and data system. Reston, VA: (USA); 2013. p. 732. Available from: https://www.acr.org/-/media/ACR/Files/RADS/BI-RADS/Mammography-Reporting.pdf, accessed on July 31, 2021.
15. American College of Radiology. ACR practice parameter for the performance of stereotactic/Tomosynthesis – Guided breast interventional procedures. Available from: https://www.acr.org/-/media/ACR/Files/Practice-Parameters/stereo-breast.pdf, accessed on July 31, 2021.
16. Huang ML, Adrada BE, Candelaria R, Thames D, Dawson D, Yang WT. Stereotactic breast biopsy: Pitfalls and pearls. Tech Vasc Interv Radiol 2014; 17 : 32-9.
17. Riedl CC, Pfarl G, Memarsadeghi M, Wagner T, Fitzal F, Rudas M, et al. Lesion miss rates and false-negative rates for 1115 consecutive cases of stereotactically guided needle-localized open breast biopsy with long-term follow-up. Radiology 2005; 237 : 847-53.
18. Caines JS, McPhee MD, Konok GP, Wright BA. Stereotaxic needle core biopsy of breast lesions using a regular mammographic table with an adaptable stereotaxic device. AJR Am J Roentgenol 1994; 163 : 317-21.
19. Bick U, Trimboi RM, Athanasiou A, Balleyguier C, Baltzer PA, Bernathova M, et al. Image-guided breast biopsy and localisation: Recommendations for information to women and referring physicians by the European Society of Breast Imaging. Insights Imaging 2020; 11 : 12.
20. Grunert P Sr., Keiner D, Oertel J. Remarks upon the term stereotaxy: A linguistic and historical note. Stereotact Funct Neurosurg 2015; 93 : 42-9.
21. Carr JJ, Hemler PF, Halford PW, Freimanis RI, Choplin RH, Chen MY. Stereotactic localization of breast lesions: How
it works and methods to improve accuracy. Radiographics 2001; 21 : 463-73.
22. Pisano ED, Fajardo LL, Caudry DJ, Sniege N, Frable WJ, Berg WA, et al. Fine-needle aspiration biopsy of nonpalpable breast lesions in a multicenter clinical trial: Results from the radiologic diagnostic oncology group V. Radiology 2001; 219 : 785-92.
23. Garg S, Mohan H, Bal A, Attiri AK, Kochhar S. A comparative analysis of core needle biopsy and fine-needle aspiration cytology in the evaluation of palpable and mammographically detected suspicious breast lesions. Diagn Cytopathol 2007; 35 : 681-9.
24. Elvecrog EL, Lechner MC, Nelson MT. Nonpalpable breast lesions: Correlation of stereotactic large-core needle biopsy and surgical biopsy results. Radiology 1993; 188 : 453-5.
25. Brenner RJ, Bassett LW, Fajardo LL, Dershaw DD, Evans WP 3rd, Hunt R, et al. Stereotactic core-needle breast biopsy: A multi-institutional prospective trial. Radiology 2001; 218 : 866-72.
26. Parker SH, Burbank F, Jackman RJ, Aucreman CJ, Cardenosa G, Cink TM, et al. Percutaneous large-core breast biopsy: A multi-institutional study. Radiology 1994; 193 : 359-64.
27. Bundred SM, Maxwell AJ, Morris J, Lim YY, Harake MJ, Whiteside S, et al. Randomized controlled trial of stereotactic 11-G vacuum-assisted core biopsy for the diagnosis and management of mammographic microcalcification. Br J Radiol 2016; 89 : 20150504.
28. Burbank F, Parker SH, Fogarty TJ. Stereotactic breast biopsy: Improved tissue harvesting with the Mammotome. Am Surg 1996; 62 : 738-44.
29. Jackman RJ, Burbank F, Parker SH, Evans WP 3rd, Lechner MC, Richardson TR, et al. Stereotactic breast biopsy of nonpalpable lesions: Determinants of ductal carcinoma in situ underestimation rates. Radiology 2001; 218 : 497-502.
30. Wilkinson L, Thomas V, Sharma N. Microlcalfication on mammography: Approaches to interpretation and biopsy. Br J Radiol 2017; 90 : 20160594.
31. NHS Breast Screening Programme. Clinical guidance for breast cancer screening assessment. Available from: https://www.gov.uk/government/publications/breast-screening-clinical-guidelines-for-screening-management, accessed on July 31, 2021.
32. Myong JH, Kang BJ, Yoon SK, Kim SH, An YY. The clinical utility of a adding lateral approach to conventional vertical approach for prone stereotactic vacuum-assisted breast biopsy. Korean J Radiol 2013; 14 : 568-75.
33. Parker SH, Klaus AJ. Performing a breast biopsy with a directional, vacuum-assisted biopsy instrument. Radiographics 1997; 17 : 1233-52.
34. Liberman L, Dershaw DD, Rosen PP, Abramson AF, Deutch BM, Hann LE. Stereotaxic 14-gauge breast biopsy: How many core biopsy specimens are needed? Radiology 1994; 192 : 793-5.
35. Mahoney MC, Newell MS. Breast intervention: How I do it. Radiology 2013; 268 : 12-24.
36. Somerville P, Seifert PJ, Destounis SV, Murphy PF, Young W. Anticoagulation and bleeding risk after core needle biopsy. AJR Am J Roentgenol 2008; 191 : 1194-7.
37. Jaffe TA, Raiiff D, Ho LM, Kim CY. Management of anticoagulant and antiplatelet medications in adults undergoing percutaneous interventions. AJR Am J Roentgenol 2015; 205 : 421-8.
38. Dershaw DD, Liberman L. Stereotactic breast biopsy: Indications and results. Oncology (Williston Park) 1998; 12 : 907-16; discussion 916, 921-2.
39. The Royal College of Pathologists. Guidelines for non-operative diagnostic procedures and reporting in breast cancer screening. Available from: https://www.rcpath.org/uploads/assets/4b16f79c-f7bd-456c-b212f557f804f66/G150-Non-op-reporting-breast-cancer-screening.pdf, accessed on August 31, 2021.
40. Liberman L, Vuolo M, Dershaw DD, Morris EA, Abramson AF, LaTrenta LR, et al. Epithelial displacement after stereotactic 11-gauge directional vacuum-assisted breast biopsy. AJR Am J Roentgenol 1999; 172 : 677-81.
41. Brenner RJ, Fajardo L, Fisher PR, Dershaw DD, Evans WP, Bassett L, et al. Percutaneous core biopsy of the breast: Effect of operator experience and number of samples on diagnostic accuracy. AJR Am J Roentgenol 1996; 166 : 341-6.
42. Atomic Energy Regulatory Board. AERB Safety manual: Regulatory inspection and enforcement in radiation facilities. Mumbai (IN): AERB, Government of India; 2014.
43. Tot T, Greve M. Radiological-pathological correlation in diagnosing breast carcinoma: The role of pathology in the multimodality era. Pathol Oncol Res 2008; 14 : 173-8.
44. Feeley L, Kiernan D, Mooney T, Flanagan F, Hargaden G, Kell M, et al. Digital mammography in a screening programme and its implications for pathology: A comparative study. J Clin Pathol 2011; 64 : 215-9.
45. Perry NM, Patani N, Milner SE, Pinker K, Mokbel K, Allgood PC, et al. The impact of digital mammography on screening a young cohort of women for breast cancer in an urban specialist breast unit. Eur Radiol 2011; 21 : 676-82.
46. Farshid G, Sullivan T, Jones S, Roder D. Performance indices of needle biopsy procedures for the assessment of screen detected abnormalities in services accredited by BreastScreen Australia. Asian Pac J Cancer Prev 2014; 15 : 10665-73.
47. Glynn CG, Farria DM, Saleman JT, Wiele KN, Hildebolt CF. Effect of transition to digital mammography on clinical outcomes. Radiology 2011; 260 : 664-70.
48. Bluekens AM, Holland R, Karssemeijer N, Broeders MJ, den Heeten GJ. Comparison of digital screening mammography and screen-film mammography in the early detection of clinically relevant cancers: A multicenter study. Radiology 2012; 265 : 707-14.
49. Weigel S, Decker T, Korschning E, Hungermann D, Böcker W, Heindel W. Calculation of digital mammographic screening: Improvement of early detection of invasive breast cancers? Radiology 2010; 255 : 738-45.
50. Jones S, Screening & Immunisations Team. Breast Screening Programme, England, 2019-20. GB: NHS Digital; 2021. p. 37.

51. National Health Service. Breast Screening Programme England-2016-17 [PAS]. England: NHS Digital; 2018.

52. BreastScreen Australia. National accreditation standards. AU: BreastScreen Australia Accreditation Review Committee; 2019.

53. Jack RH, Møller H, Robson T, Davies EA. Breast cancer screening uptake among women from different ethnic groups in London: A population-based cohort study. BMJ Open 2014; 4: e005586.

54. Evans A. The diagnosis and management of pre-invasive breast disease: Radiological diagnosis. Breast Cancer Res 2003; 5: 250-3.

55. Fueger BJ, Clauser P, Kapetas P, Pötsch N, Helbich TH, Baltzer PA. Can supplementary contrast-enhanced MRI of the breast avoid needle biopsies in suspicious microcalcifications seen on mammography? A systematic review and meta-analysis. Breast 2021; 56: 53-60.

56. Di Ninno AA, Mello GG, Torres US, Shimizu C, Tucunduva TC, Reis FR, et al. MRI as a complementary tool for the assessment of suspicious mammographic calcifications: Does it have a role? Clin Imaging 2021; 74: 76-83.

57. Taskin F, Kalayci CB, Tuncbilek N, Soydemir E, Kurt N, Kaya H, et al. The value of MRI contrast enhancement in biopsy decision of suspicious mammographic microcalcifications: A prospective multicenter study. Eur Radiol 2021; 31: 1718-26.

58. Song L, Wei X, Wang Q, Wang Y. Detection of microcalcification clusters regions in mammograms combining discriminative deep belief networks. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 2021; 38: 268-75.

59. Liu H, Chen Y, Zhang Y, Wang L, Luo R, Wu H, et al. A deep learning model integrating mammography and clinical factors facilitates the malignancy prediction of BI-RADS 4 microcalcifications in breast cancer screening. Eur Radiol 2021; 31: 5902-12.

60. Kedar A, Kannan R, Mehrotra R, Hariprasad R. Implementation of population-based cancer screening program in a pilot study from India: Views from health personnel. Indian J Community Med 2019; 44: 68-70.

61. Rew DA, Rayter Z. Breast screening in India: A UK perspective on the practicalities. Indian J Surg Oncol 2012; 3: 17-9.

62. Breast Imaging Society, India. Best practice guidelines in breast imaging. Available from: http://www.bisi.co.in/mammography1.html, accessed on April 1, 2020.

63. Census of India. CensusInfo India 2011, census provisional population totals; 2011. Available from: http://www.dataforall.org/dashboard/censusinfoindia_pca/, accessed on April 14, 2020.

64. Social Statistics Division. National Statistical Office, Ministry of Statistics and Programme Implementation, Government of India. Women and Men in India 2019. Available from: http://mospi.nic.in/sites/default/files/reports_and_publication/statistical_publication/Women_Men/Women_and_Men_31_%20Mar_2020.pdf, accessed on July 21, 2021.

65. Pham R, Constantinou N, Plecha D. Utilizing the hub-and-spoke model to deliver quality breast imaging in a large health system. J Breast Imaging 2019; 1: 51-5.

For correspondence: Dr Suma Chakrabartii, Peerless Hospital & B.K. Roy Research Centre, 360, Pancha Sayar Road, Kolkata 700 094, West Bengal, India

e-mail: sumadoc@gmail.com